Non-Stimulant Medications for ADHD Treatment

Introduction to Non-Stimulant Medications

The American Academy of Pediatrics recommends atomoxetine as the first-line non-stimulant choice for ADHD treatment, due to its extensive evidence base across the entire lifespan from children to adults 1

Atomoxetine is a selective norepinephrine reuptake inhibitor with an effect size of approximately 0.7 compared to placebo, demonstrating consistent efficacy in reducing core ADHD symptoms, as supported by the American Academy of Pediatrics 1, 2
The American Academy of Pediatrics suggests that atomoxetine provides "around-the-clock" symptom coverage with once-daily or split dosing options, offering continuous therapeutic effects throughout the day and evening 1, 2

The American Academy of Pediatrics recommends atomoxetine as the first-line non-stimulant for patients with comorbid substance use disorders, comorbid tic disorders or Tourette's syndrome, and comorbid anxiety disorders, due to its lower risk of symptom exacerbation 1
The dosing strategy for atomoxetine is to start at 40 mg/day in adults, titrate to target dose of 80-100 mg/day, as recommended by the American Academy of Pediatrics 1, 2

The FDA requires monitoring of patients taking atomoxetine for suicidal ideation, especially during the first few weeks of treatment and during dose adjustments, as stated in the FDA Black Box Warning 1, 2
Baseline assessment should include blood pressure, heart rate, weight, and suicidality screening, as recommended by the American Academy of Pediatrics 1

The American Academy of Pediatrics states that no non-stimulant medication, including atomoxetine, has received sufficient rigorous study in preschool-aged children to be recommended 1
Atomoxetine is metabolized through CYP2D6, and dose adjustments may be needed for poor metabolizers or when used with CYP2D6 inhibitors, as recommended by the American Academy of Pediatrics 2

The American Academy of Pediatrics advises against expecting immediate response to atomoxetine, as it requires patience and consistent dosing for 6-12 weeks before determining treatment response 1, 2
The American Academy of Pediatrics recommends not overlooking suicidality monitoring, particularly in the initial treatment phase, due to the FDA Black Box Warning 1, 2